More potentially radioactive shrimp recalled in 17 states. See list.

The FDA expanded a recall of frozen raw shrimp after products processed by PT. Bahari Makmur Sejati tested positive for radioactive cesium-137, with Direct Source Seafood LLC recalling approximately 83,800 bags sold under Market 32 and Waterfront Bistro (specific UPCs and best-by dates noted) at retailers including Price Chopper, Jewel-Osco, Albertsons, Safeway, Lucky and Supermarket across 17 states. PT. Bahari Makmur Sejati has been placed on an import alert preventing its products from entering the U.S.; no illnesses have been reported. The development creates regulatory-led supply disruptions and reputational risk for affected retailers and importers and warrants monitoring for further trade and inventory impacts.

Analysis

Market structure: The recall concentrates downside on retailers and importers carrying private‑label frozen shrimp (notably Albertsons/ACI and regional chains like Price Chopper), while diversified national grocers (Costco/COST, Kroger/KR) and foodservice companies with domestic sourcing see relative demand capture. Expect a near‑term re‑routing of orders to domestic suppliers that could lift spot shrimp prices by a low‑teens percentage if import volumes are constrained for >1–3 months, improving pricing power for alternative suppliers.

Risk assessment: Tail risks include a broader contamination finding that expands FDA import alerts beyond PT. Bahari Makmur Sejati to multiple Indonesian processors (low probability, high impact) — that would materially raise testing and compliance costs (10–30% on imports) and force multi‑quarter supplier transitions. Immediate (days) risk is reputational/footfall hit and inventory write‑downs; short term (weeks–months) is margin pressure through holiday sales; long term (quarters) is permanent supplier reallocation and higher per‑unit sourcing costs.

Trade implications: Tactical opportunities favor long, low‑beta exposure to large, diversified grocers (COST, KR) and short concentrated private‑label exposure (ACI). Use options to limit downside: buy 3‑month ACI put spreads to express downside and consider modest call exposure to lab/testing beneficiaries (Thermo Fisher/TMO) if FDA testing requirements broaden. Cross‑asset: minimal FX/bond moves expected unless recalls cascade to major food categories.

Contrarian angle: The market may overstate revenue impact — frozen shrimp is likely <1% of most grocers’ revenue, so broad selloffs are mispriced; buy dips in KR/COST on >3–5% pullbacks. Historical precedents (food recalls) show 3–12 month normalization once supply chains requalify, creating a mean‑reversion trade into quality grocers and selected testing/inspection names.

Key Decisions for Investors

• Establish a 1.5% portfolio long position in Costco (COST) within 7 trading days; target +6–12% upside over 3–6 months, stop‑loss at -6%, thesis: lower reliance on small imported seafood SKUs and stronger private‑label QA.
• Establish a 2.0% notional bearish position on Albertsons (ACI) via a 3‑month 10% OTM put spread (debit), sized to 2% of portfolio; if FDA expands import alerts to ≥3 suppliers or recalled volume >500k units, increase to 3.5%.
• Implement a pair trade: long Kroger (KR) 1.5% vs short Albertsons (ACI) 1.5% for 1–3 months; close the pair if ACI outperforms KR by >15% or if FDA public guidance reduces contamination concerns within 30 days.
• Buy a tactical 0.75% notional in Thermo Fisher (TMO) 6‑month calls (or equivalent exposure to lab/testing) if FDA issues new mandatory testing requirements for imported seafood within 30 days — expected beneficiary of higher testing capex and recurring demand.